Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 4/20 | 0.77 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2441866 | 0.86 | ANPEP (0.75) | ANPEPHRH3MEN1KMT2A | |
| SCHEMBL2441868 | 0.85 | ANPEP (0.57) | ANPEPMEN1KMT2A | |
| SCHEMBL16751823 | 0.83 | ANPEP (0.78) | ANPEPHRH3MEN1KMT2A | |
| SCHEMBL2443305 | 0.78 | ANPEP (0.63) | ANPEPHRH3 | |
| SCHEMBL2443686 | 0.75 | HRH3 (0.72) | ANPEPHRH3MEN1KMT2A | |
| SCHEMBL2443281 | 0.75 | HRH3 (0.88) | HRH3MEN1KMT2A | |
| SCHEMBL2443841 | 0.73 | ANPEP (0.63) | ANPEPHRH3MEN1KMT2A | |
| SCHEMBL12223657 | 0.73 | HRH3 (0.68) | HRH3MEN1KMT2A | |
| SCHEMBL2445934 | 0.71 | HRH3 (0.93) | HRH3MEN1KMT2A | |
| SCHEMBL8545622 | 0.71 | HRH3 (0.98) | HRH3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9044478-B2 | Use of 1,4-bis (3-aminoalkyl) piperazine derivatives in the treatment of neurodegenerative diseases | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2015-06-02 | — | — | US | claimed |
| US-20090149464-A1 | Use of 1,4-bis (3-aminoalkyl) piperazine derivatives in the treatment of neurodegenerative diseases | UNIVERSITE DU DROIT ET DE LA SANTE- LILLE II (FR) | 2009-06-11 | — | — | US | claimed |
| US-9044478-B2 | Use of 1,4-bis (3-aminoalkyl) piperazine derivatives in the treatment of neurodegenerative diseases | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2015-06-02 | — | — | US | disclosed |
| EP-1809288-B1 | USE OF 1,4-BIS (3-AMINOALKYL) PIPERAZINE DERIVATIVES IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | INST NAT SANTE RECH MED (FR) | 2011-09-14 | — | — | EP | disclosed |
| US-20090149464-A1 | Use of 1,4-bis (3-aminoalkyl) piperazine derivatives in the treatment of neurodegenerative diseases | UNIVERSITE DU DROIT ET DE LA SANTE- LILLE II (FR) | 2009-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149464-A1 | Use of 1,4-bis (3-aminoalkyl) piperazine derivatives in the treatment of neurodegenerative diseases | PSEN1, PSEN2, SNCA | ANPEP 555/4885HRH3 3217/4885MEN1 3397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.